Product image of Letrozole Sandoz (Letrozole) supplied by GNH India

Letrozole Sandoz

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Sandoz (Letrozole)

Letrozole, the active ingredient in Letrozole Sandoz, is a non‑steroidal aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant and metastatic settings.

GNH India supplies Letrozole Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring product quality, regulatory compliance and reliable logistics across global markets. Our distribution network adheres to stringent temperature and handling standards to maintain drug integrity.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer pathways.

  • Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels.
  • Adjuvant treatment of early‑stage disease: decreases risk of recurrence after surgery.
  • Metastatic hormone‑sensitive breast cancer: helps control disease progression in advanced cases.

How It Works

  • Letrozole selectively and non‑steroidally inhibits the aromatase enzyme (CYP19A1), which catalyzes the conversion of androstenedione and testosterone to estrone and estradiol. By blocking this peripheral aromatization, systemic estrogen concentrations fall, depriving estrogen‑dependent breast tumor cells of a growth stimulus. The inhibition is reversible and dose‑dependent, providing sustained estrogen suppression with once‑daily oral dosing.

Side Effects

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Fatigue: persistent tiredness affecting daily activities.
  • Joint and muscle pain: arthralgia or myalgia.
  • Nausea: upset stomach, sometimes with vomiting.
  • Headache: mild to moderate intensity.
  • Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

  • Severe liver injury: elevated transaminases or hepatic failure.
  • Bone fractures: increased risk of osteoporosis‑related breaks.
  • Pulmonary embolism: blood clot in the lungs, requiring urgent care.
  • Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty.
  • QT interval prolongation: potential cardiac arrhythmia.

Precautions & Warnings

Before initiating Letrozole, several safety considerations should be reviewed.

  • Pregnancy contraindication: drug is category X and must not be used during pregnancy.
  • Menopausal status: indicated only for postmenopausal women; assess menopausal criteria before use.
  • Bone health monitoring: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation.
  • Liver function: perform baseline hepatic tests and monitor periodically.
  • Drug interaction review: check concomitant medications for CYP2A6 inhibitors or estrogen‑containing therapies.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Avoid Interactions

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP2A6 inhibitors: may increase letrozole plasma concentrations.
  • Estrogen‑containing hormone therapy: antagonizes therapeutic effect.
  • Tamoxifen: concurrent use may reduce effectiveness of both agents.

Moderate Interactions (Monitor Closely)

  • Warfarin: letrozole may alter anticoagulant effect; monitor INR.
  • CYP3A4 inducers (e.g., rifampicin): may lower letrozole exposure.
  • Antidepressants affecting QT interval: monitor cardiac rhythm.

Frequently Asked Questions

Letrozole Sandoz is indicated as an endocrine therapy for hormone receptor‑positive breast cancer in postmenopausal women. It is used in both adjuvant settings to reduce recurrence risk after surgery and in metastatic disease to help control tumor progression.

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens. By blocking this conversion, circulating estrogen levels drop, depriving estrogen‑dependent breast cancer cells of a key growth signal.

The prescribed dose of Letrozole is determined by the treating physician based on clinical guidelines and individual patient factors. Typically, it is administered as a once‑daily oral tablet, but the exact strength and regimen are individualized.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy and must not be used by breastfeeding women. Effective contraception is required for the duration of treatment and for a defined period after discontinuation.

To order Letrozole Sandoz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole belongs to the aromatase inhibitor class, similar to anastrozole and exemestane, and provides more complete estrogen suppression than selective estrogen receptor modulators such as tamoxifen. Choice of therapy depends on patient‑specific factors, prior treatment history and physician assessment.

Letrozole tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging. Protect them from moisture, light and excessive heat to maintain potency throughout the shelf‑life.

Letrozole is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, and the exact timing should follow the prescriber's instructions.

Serious risks include severe liver injury, increased incidence of bone fractures due to reduced estrogen, pulmonary embolism, severe allergic reactions such as anaphylaxis, and cardiac arrhythmias related to QT prolongation. Patients should be monitored for these events.

Letrozole should not be used by pregnant women, premenopausal women, individuals with known hypersensitivity to letrozole, or patients with severe hepatic impairment. Contraindications are outlined in the prescribing information and should be reviewed by the healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT